SG11202005526WA - Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis - Google Patents

Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis

Info

Publication number
SG11202005526WA
SG11202005526WA SG11202005526WA SG11202005526WA SG11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA
Authority
SG
Singapore
Prior art keywords
formulations
prevention
treatment
atopic dermatitis
peptide immunogens
Prior art date
Application number
SG11202005526WA
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of SG11202005526WA publication Critical patent/SG11202005526WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018Lipids, e.g. in lipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
SG11202005526WA 2017-12-11 2018-12-11 Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis SG11202005526WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597130P 2017-12-11 2017-12-11
PCT/US2018/065025 WO2019118512A2 (fr) 2017-12-11 2018-12-11 Immunogènes peptidiques d'il-31 et formulations correspondantes pour le traitement et/ou la prévention de la dermatite atopique

Publications (1)

Publication Number Publication Date
SG11202005526WA true SG11202005526WA (en) 2020-07-29

Family

ID=66820956

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005526WA SG11202005526WA (en) 2017-12-11 2018-12-11 Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis

Country Status (12)

Country Link
US (1) US20210079054A1 (fr)
EP (1) EP3724218A2 (fr)
JP (1) JP7250032B2 (fr)
KR (1) KR20210009296A (fr)
CN (1) CN111448208B (fr)
AU (1) AU2018383708B2 (fr)
BR (1) BR112020011308A2 (fr)
CA (1) CA3085318A1 (fr)
MX (1) MX2020006105A (fr)
SG (1) SG11202005526WA (fr)
TW (1) TWI741241B (fr)
WO (1) WO2019118512A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156180A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
AU2019236328A1 (en) 2018-03-16 2020-09-10 Zoetis Services Llc Peptide vaccines against Interleukin-31
WO2021041972A1 (fr) * 2019-08-29 2021-03-04 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
BR112022014845A2 (pt) * 2020-01-28 2022-12-13 United Biomedical Inc Imunógenos peptídicos de alvejamento de pcsk9 e formulações do mesmo para prevenção e tratamento de distúrbios mediados por pcsk9
EP4247848A1 (fr) * 2020-11-23 2023-09-27 Scout Bio, Inc. Molécules de liaison à l'antigène et leurs utilisations
WO2023161526A1 (fr) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg Conjugué constitué de ou comprenant au moins un ss-glucane ou un mannane

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
WO2016198470A2 (fr) 2015-06-08 2016-12-15 Lophius Biosciences Gmbh Composition pour la détermination de la réactivité immunitaire à médiation cellulaire
EP3347040A1 (fr) * 2015-09-08 2018-07-18 Universität Zürich Traitement d'une hypersensibilité aux piqûres d'insectes
BR112018071965A2 (pt) * 2016-04-27 2019-03-06 Benchmark Animal Health Ltd tratamento da dermatite atópica canina

Also Published As

Publication number Publication date
BR112020011308A2 (pt) 2020-11-17
EP3724218A2 (fr) 2020-10-21
RU2020122924A (ru) 2022-01-14
CN111448208A (zh) 2020-07-24
AU2018383708A1 (en) 2020-07-16
CA3085318A1 (fr) 2019-06-20
KR20210009296A (ko) 2021-01-26
AU2018383708B2 (en) 2023-10-26
CN111448208B (zh) 2024-02-27
JP2021510169A (ja) 2021-04-15
TWI741241B (zh) 2021-10-01
WO2019118512A2 (fr) 2019-06-20
JP7250032B2 (ja) 2023-03-31
MX2020006105A (es) 2020-11-09
WO2019118512A3 (fr) 2020-04-09
US20210079054A1 (en) 2021-03-18
TW201927813A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
IL277648A (en) Medical microbiota for the treatment and/or prevention of food allergy
IL268406A (en) Preparations and methods for treating hemoglobin diseases
SG11202005526WA (en) Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
IL290150A (en) Compounds and methods for treating chronic pain
SG10201402819WA (en) Composition for prevention and treatment of joint pain and the method of preparation thereof
ZA201905851B (en) Peptides and methods for the treatment of diabetes
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
EP3518918A4 (fr) Méthodes et compositions pharmaceutiques pour le traitement de la stéatohépatite non alcoolique
HK1257853A1 (zh) 用於治療和預防放射性皮炎的組合物和方法
EP3423064A4 (fr) Formulations de testostérone et méthodes de traitement associées
IL272121A (en) Preparation and methods for the treatment of myopia
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
EP3468540A4 (fr) Compositions pharmaceutiques et méthodes de traitement du cancer
HK1259125A1 (zh) 治療和/或預防與血液相關病症的方法和製劑
EP3697387A4 (fr) Combinaison d'as1411 et de sapc-dops pour le traitement du glioblastome multiforme
EP3518951A4 (fr) Compositions et méthodes pour le traitement d'affections orthopédiques
IL272147A (en) Methods and preparations for the treatment of cancer
GB201614415D0 (en) Enzymes for the treatment of human enterometabolic dysfunction
SG11202004005RA (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
EP3131635A4 (fr) Compositions et méthodes de traitement ou de prévention de la tuberculose
HK1252359A1 (zh) 用於治療疼痛的曲唑酮和加巴噴丁的組合
EP3525787A4 (fr) Méthodes de traitement et compositions pharmaceutiques utilisant bcn057 ou bcn512
IL265242B (en) Compounds for the treatment of hypertension and/or fibrosis